구조모아 (StructureMoa)항암 chemical structure spider web
방문Janssen ResearchDevelopmentLLC
Irinotecan Hydrochloride(Janssen Research & Development, LLC)은 Advanced Malignant Solid Neoplasm 표적 치료제로, Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: targeting VEGF have demonstrated clinical benefit, their efficacy is frequently limited by adaptive resistance, systemic toxicity, and incomplete suppression of VEGF signaling. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 57% (ClinicalTrials.gov NCT00551421). PK: t½ 12 h. 차별점: novel monoamine oxidase-B inhibitors via structure-based modeling to treat neurodegenerative diseases.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Advanced Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8
Discontinued
2026-09-02
Data Confidence · Low
Development Signal · Watch
novel monoamine oxidase-B inhibitors via structure-based modeling to treat neurodegenerative diseases
targeting VEGF have demonstrated clinical benefit, their efficacy is frequently limited by adaptive resistance, systemic toxicity, and incomplete suppression of VEGF signaling
apoptosis pathways
biomarkers for diagnosis, drug resistance, sensitivity and prognosis
resistance to Irinotecan across multiple cell lines
구조화 데이터
orthotopic CRC mouse
rat
12
IC50 2.4
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Janssen ResearchDevelopmentLLC
Irinotecan Hydrochloride(Janssen Research & Development, LLC)은 Advanced Malignant Solid Neoplasm 표적 치료제로, Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: targeting VEGF have demonstrated clinical benefit, their efficacy is frequently limited by adaptive resistance, systemic toxicity, and incomplete suppression of VEGF signaling. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 57% (ClinicalTrials.gov NCT00551421). PK: t½ 12 h. 차별점: novel monoamine oxidase-B inhibitors via structure-based modeling to treat neurodegenerative diseases.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Advanced Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8
Discontinued
2026-09-02
Data Confidence · Low
Development Signal · Watch
novel monoamine oxidase-B inhibitors via structure-based modeling to treat neurodegenerative diseases
targeting VEGF have demonstrated clinical benefit, their efficacy is frequently limited by adaptive resistance, systemic toxicity, and incomplete suppression of VEGF signaling
apoptosis pathways
biomarkers for diagnosis, drug resistance, sensitivity and prognosis
resistance to Irinotecan across multiple cell lines
구조화 데이터
orthotopic CRC mouse
rat
12
IC50 2.4
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.